Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9394 |
High Similarity |
NPD943 |
Approved |
0.8978 |
High Similarity |
NPD651 |
Clinical (unspecified phase) |
0.8621 |
High Similarity |
NPD1512 |
Approved |
0.8523 |
High Similarity |
NPD1934 |
Approved |
0.8483 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8467 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8355 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8333 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.8333 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.8333 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.831 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8222 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.8182 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.8156 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8146 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.8138 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8113 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8105 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8099 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.8069 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8069 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8042 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7963 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7935 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7933 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7926 |
Intermediate Similarity |
NPD9268 |
Approved |
0.7914 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7901 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7885 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7866 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7852 |
Intermediate Similarity |
NPD6190 |
Approved |
0.784 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7834 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7834 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7791 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7786 |
Intermediate Similarity |
NPD1470 |
Approved |
0.7758 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7756 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7754 |
Intermediate Similarity |
NPD1201 |
Approved |
0.7748 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7748 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7744 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7692 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7635 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7595 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7582 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7564 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7535 |
Intermediate Similarity |
NPD1164 |
Approved |
0.7534 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7534 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7533 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7531 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7517 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7516 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7515 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7484 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7469 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7468 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7453 |
Intermediate Similarity |
NPD919 |
Approved |
0.7448 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7445 |
Intermediate Similarity |
NPD405 |
Clinical (unspecified phase) |
0.7421 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7421 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.74 |
Intermediate Similarity |
NPD5404 |
Approved |
0.74 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.74 |
Intermediate Similarity |
NPD5408 |
Approved |
0.74 |
Intermediate Similarity |
NPD5406 |
Approved |
0.74 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7375 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7355 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7338 |
Intermediate Similarity |
NPD3300 |
Phase 2 |
0.7328 |
Intermediate Similarity |
NPD1237 |
Approved |
0.732 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.731 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7305 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7296 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7278 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.726 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7239 |
Intermediate Similarity |
NPD74 |
Approved |
0.7239 |
Intermediate Similarity |
NPD9266 |
Approved |
0.7208 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7194 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7192 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD9570 |
Approved |
0.7164 |
Intermediate Similarity |
NPD9267 |
Approved |
0.7164 |
Intermediate Similarity |
NPD9264 |
Approved |
0.7164 |
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.7164 |
Intermediate Similarity |
NPD9263 |
Approved |
0.7152 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7134 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7134 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7134 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7133 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7099 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7097 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7092 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7073 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7069 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7059 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7055 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7044 |
Intermediate Similarity |
NPD920 |
Approved |
0.7034 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7032 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7025 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7024 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7014 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.7013 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7013 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7012 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7006 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD6651 |
Approved |
0.6933 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6929 |
Remote Similarity |
NPD9281 |
Approved |
0.6923 |
Remote Similarity |
NPD1243 |
Approved |
0.6923 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.6917 |
Remote Similarity |
NPD940 |
Approved |
0.6917 |
Remote Similarity |
NPD846 |
Approved |
0.6914 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6905 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6894 |
Remote Similarity |
NPD1653 |
Approved |
0.6893 |
Remote Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.6883 |
Remote Similarity |
NPD3748 |
Approved |
0.6879 |
Remote Similarity |
NPD8166 |
Discontinued |
0.6866 |
Remote Similarity |
NPD9261 |
Approved |
0.6852 |
Remote Similarity |
NPD3455 |
Phase 2 |
0.6835 |
Remote Similarity |
NPD2309 |
Approved |
0.6833 |
Remote Similarity |
NPD6535 |
Approved |
0.6833 |
Remote Similarity |
NPD6534 |
Approved |
0.6829 |
Remote Similarity |
NPD37 |
Approved |
0.6826 |
Remote Similarity |
NPD6234 |
Discontinued |
0.6821 |
Remote Similarity |
NPD5953 |
Discontinued |
0.6821 |
Remote Similarity |
NPD2313 |
Discontinued |
0.6821 |
Remote Similarity |
NPD3764 |
Approved |
0.6802 |
Remote Similarity |
NPD7286 |
Phase 2 |
0.6797 |
Remote Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.6779 |
Remote Similarity |
NPD2798 |
Approved |
0.6776 |
Remote Similarity |
NPD520 |
Approved |
0.6774 |
Remote Similarity |
NPD2799 |
Discontinued |
0.6772 |
Remote Similarity |
NPD3400 |
Discontinued |
0.6765 |
Remote Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.6759 |
Remote Similarity |
NPD9384 |
Approved |
0.6759 |
Remote Similarity |
NPD9381 |
Approved |
0.6758 |
Remote Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.675 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6748 |
Remote Similarity |
NPD3226 |
Approved |
0.6746 |
Remote Similarity |
NPD7199 |
Phase 2 |
0.6743 |
Remote Similarity |
NPD5028 |
Approved |
0.6743 |
Remote Similarity |
NPD5026 |
Approved |
0.6743 |
Remote Similarity |
NPD36 |
Approved |
0.6743 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6743 |
Remote Similarity |
NPD5034 |
Approved |
0.6743 |
Remote Similarity |
NPD4955 |
Approved |
0.6743 |
Remote Similarity |
NPD4954 |
Approved |
0.6739 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6739 |
Remote Similarity |
NPD6776 |
Approved |
0.6739 |
Remote Similarity |
NPD6779 |
Approved |
0.6739 |
Remote Similarity |
NPD6782 |
Approved |
0.6739 |
Remote Similarity |
NPD6777 |
Approved |
0.6739 |
Remote Similarity |
NPD6780 |
Approved |
0.6739 |
Remote Similarity |
NPD6778 |
Approved |
0.6739 |
Remote Similarity |
NPD6781 |
Approved |
0.6735 |
Remote Similarity |
NPD9717 |
Approved |
0.6721 |
Remote Similarity |
NPD7700 |
Phase 2 |
0.6721 |
Remote Similarity |
NPD7699 |
Phase 2 |
0.6707 |
Remote Similarity |
NPD4965 |
Approved |
0.6707 |
Remote Similarity |
NPD4967 |
Phase 2 |
0.6707 |
Remote Similarity |
NPD4966 |
Approved |
0.6705 |
Remote Similarity |
NPD5035 |
Approved |
0.6691 |
Remote Similarity |
NPD4750 |
Phase 3 |
0.6689 |
Remote Similarity |
NPD6832 |
Phase 2 |
0.6688 |
Remote Similarity |
NPD1933 |
Approved |
0.6688 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6686 |
Remote Similarity |
NPD5030 |
Phase 2 |
0.6686 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.6685 |
Remote Similarity |
NPD5037 |
Approved |
0.6685 |
Remote Similarity |
NPD5038 |
Approved |
0.6685 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD3299 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD1610 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD258 |
Approved |
0.6667 |
Remote Similarity |
NPD257 |
Approved |
0.6667 |
Remote Similarity |
NPD5242 |
Approved |
0.6647 |
Remote Similarity |
NPD7228 |
Approved |
0.6631 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6629 |
Remote Similarity |
NPD5036 |
Approved |
0.6624 |
Remote Similarity |
NPD6100 |
Approved |
0.6624 |
Remote Similarity |
NPD6099 |
Approved |
0.6623 |
Remote Similarity |
NPD3059 |
Approved |
0.6623 |
Remote Similarity |
NPD826 |
Approved |
0.6623 |
Remote Similarity |
NPD3061 |
Approved |
0.6623 |
Remote Similarity |
NPD825 |
Approved |
0.6623 |
Remote Similarity |
NPD3062 |
Approved |
0.6622
|
Remote Similarity |
NPD3972 |
Approved |